News

INmune Bio Inc. Scheduled to Discuss Q1 2025 Results Soon

INmune Bio Inc. Scheduled to Discuss Q1 2025 Results Soon

Upcoming Conference Call for INmune Bio Inc.

INmune Bio Inc. (NASDAQ: INMB), a pioneering clinical-stage biotechnology company known for its innovative approaches to treating Alzheimer’s Disease through neuroinflammation research, is set to host a conference call soon. This event aims to discuss its financial results for the first quarter of 2025, alongside important corporate developments.

Call Details for Shareholders

Investors and interested parties are encouraged to join the call, scheduled for May 8, 2025, at 4:30 PM EDT. Participants should dial in 5 to 10 minutes prior to the start time and mention the INmune Bio First Quarter Conference Call when prompted by the operator.

Accessing the Live Webcast

For those unable to attend the call, a live audio webcast will be made available. This can be accessed through their official website shortly before the scheduled time, ensuring that everyone can stay informed about INmune Bio’s progress and updates.

About INmune Bio Inc.

Based in Boca Raton, Florida, INmune Bio Inc. is at the forefront of clinical research with a focus on therapies that harness the body's innate immune system to combat various diseases. The company has developed three main product platforms. One of them, the Dominant-Negative Tumor Necrosis Factor (DN-TNF), is designed to neutralize soluble TNF, addressing its role in immune dysfunction. This platform is currently undergoing clinical trials to assess its efficacy in treating Mild Alzheimer’s disease, Mild Cognitive Impairment, and treatment-resistant depression.

Innovations in Immunology

Another platform, the Natural Killer Cell Priming Platform, includes the development of INKmune®, which primes a patient’s natural killer cells to help eradicate cancer-related minimal residual disease. This treatment is currently being evaluated in trials focusing on metastatic castration-resistant prostate cancer.

The third innovative approach is CORDStrom™, a novel platform based on human umbilical cord-derived mesenchymal Stromal/Stem cells. This program has recently completed a blinded randomized trial aimed at addressing recessive dystrophic epidermolysis bullosa, highlighting the significant potential of INmune Bio’s offerings.

Understanding INmune Bio's Mission

INmune Bio is dedicated to employing precision medicine to tackle diseases driven by chronic inflammation and oncology. The pursuit of developing transformative therapies that can positively impact patients’ lives showcases their commitment to advancing healthcare solutions. As they work towards this mission, maintaining open communication with stakeholders remains a priority.

Contacting INmune Bio Inc.

For further inquiries or to understand more about their advancements, you can reach out directly to their contact points. David Moss, the CFO, is available at (561) 710-0512 or via email at info@inmunebio.com. Additionally, Daniel Carlson, the Head of Investor Relations, is also accessible for any investor-related questions at (415) 509-4590 or dcarlson@inmunebio.com.

Frequently Asked Questions

What is the purpose of the upcoming call?

The call is intended to discuss INmune Bio's financial results and provide an update on the company's progress and initiatives.

When will the conference call take place?

The conference call is scheduled for May 8, 2025, at 4:30 PM EDT.

How can I access the conference call?

Participants can dial in by following the provided instructions or access the live audio webcast through the INmune Bio website.

What are the main product platforms of INmune Bio?

INmune Bio has three key platforms focused on treating conditions related to inflammation, cancer, and neurodegeneration, namely DN-TNF, INKmune®, and CORDStrom™.

Who can I contact for more information?

Contact David Moss or Daniel Carlson for inquiries related to the company or investments at the provided emails and phone numbers.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

China Southern Airlines Marks 70th Anniversary in NYC

Updated Category News Views 4

Taking Flight with Legacy and Tradition Throwing a bash on Times Square isn't just about flash; it's about letting folks know you mean business. And China Southern Airlines has been doing just that for 70 years. Imagine starting from Guangzhou and ending up splashed across New York City's giant LED screens—talk about a journey! From Humble Roots to Global Network...

Continue Reading
CVS Health Under Fire: Fiduciary Duty Breach?

Updated Category News Views 3

CVS Under Regulatory Spotlight for Fiduciary Breaches You'd think by now companies would have their fiduciary ducks in a row. But here we are, with CVS Health Corporation (NYSE: CVS) catching heat from the legal eagles over at Halper Sadeh LLC. The knife’s out for some of the big wigs – apparently, there's chatter they might’ve slipped on their duty to play nice...

Continue Reading
Quay Sunglasses: Luxury Looks, Affordable Prices

Updated Category News Views 3

Ah, sunglasses—the quintessential accessory that screams both practicality and style. A million-dollar look without the million-dollar expense? That's where Quay comes in. They've been recognized by Expert Consumers, no less, as some of the best-in-class for affordable luxury eye candy out there—aimed at shoppers who want the designer vibe without the hemorrhaging...

Continue Reading
Endurance Energy's Modular Tech Revs Up Southeast Asia

Updated Category News Views 4

Modular Solutions Steal the Show in Bangkok When a company draws 59,468 attendees from over 150 countries, folks pay attention—and that was exactly the scene at Gastech 2026 in Bangkok. The name buzzing on many lips? Endurance Energy. These guys showcased a fresh take on energy logistics with their skid-mounted liquefaction tech, turning heads with their Southeast Asia...

Continue Reading
PACS Group Faces Legal Scrutiny: What to Watch

Updated Category News Views 5

PACS Group: Legal Storm Brewing Welcome to the latest saga in the volatile theater of corporate governance. PACS Group, Inc., ticker symbol NYSE:PACS, is under the microscope, and not for debuting a groundbreaking product or hitting a stock milestone. Nope, instead we've got Halper Sadeh LLC out of New York investigating some possible hanky-panky from PACS directors and...

Continue Reading
Timur Turlov Leads FIDE with Chess and Digital Focus

Updated Category News Views 5

An Unpredicted Victory in Samarkand Well, color me surprised. Timur Turlov's made waves by clinching the role of FIDE President at the General Assembly in Samarkand. This one's quite the turn for the chess world—Kazakhstan’s own stepping up to run the whole show. This isn't just some ceremonial post either. Turlov, who's been pulling strings over at the Kazakhstan...

Continue Reading
AI and Storytelling Make Waves in Science Education

Updated Category News Views 5

University's Innovative Approach to Learning Alright, here's something you don't see every day. The University of Phoenix managed to snag some kudos from an academic journal for using AI and storytelling to teach environmental science. That's like hitting two bulls-eyes with one shot in the world of education. The recognition from Glacies for this Editor's Choice paper...

Continue Reading
Farm Aid 2026: A Resilient Tribute to Family Farmers

Updated Category News Views 5

Shining a Light on Essential Family Farmers Every year, thousands gather for Farm Aid to back the unsung heroes who put food on our plates. In 2026, the scene shifted to the amphitheater at Virginia Beach, where an epic lineup of music took stage not just to entertain but to underline a critical issue—family farmers are fighting for survival. These folks aren't merely...

Continue Reading
Jackson Wang's Fantasy IP Hits Hong Kong Stage

Updated Category News Views 5

A Star-Studded Fantasy Comes Alive Hong Kong isn't just about dim sum and skyline views—it's a magnet for celebrity showcases, and this time, Jackson Wang's pulling the strings. The guy's ventured beyond music and idol fame, diving head-first into creative visuals with his fantasy IP, "Under the Castle" (UTC). Pairing up with Ocean Park's Halloween Fest, he's cooked up...

Continue Reading
AST SpaceMobile Faces Class Action Over Misstatements

Updated Category News Views 4

What's Going On with AST SpaceMobile? Kicking off with a heavy hitter here, folks. AST SpaceMobile, Inc., trading under NASDAQ:ASTS, is under a securities fraud spotlight. We're talking allegations piled higher than a morning stack of pancakes. If you picked up any ASTS shares between March 4, 2025, and July 15, 2026, you're in on this rough ride. There's a class action...

Continue Reading

Top 5 Most Recently Viewed Articles

Find Comfort and Assurance This Fall at Gate of Heaven

Updated Category News Views 97

Experience Comfort and Connection This Fall at Gate of Heaven This autumn, as the leaves turn and a spirit of reflection emerges, families are warmly invited to the Gate of Heaven Cemetery and Mausoleum for a special Fall Open House weekend. This event aims to foster connections among families while providing valuable insights into the significance of memorial planning....

Continue Reading
Lauren Cody to Lead Orangetheory Fitness as Brand President

Updated Category News Views 491

Lauren Cody Takes the Helm at Orangetheory Fitness Purpose Brands, LLC has exciting news! The organization, known for its significant contributions to the fitness, health, and wellness sector, is proudly announcing the appointment of Lauren Cody as the brand president of Orangetheory Fitness. With over twenty-five years of rich experience in leading substantial franchise...

Continue Reading
BofA Downgrades Nissan: Competition Fears and Sales Outlook

Updated Category News Views 126

BofA Downgrades Nissan Shares Due to Rising Competition BofA Securities has decided to downgrade Nissan Motor Co Ltd (OTC: NSANY), changing its stock rating from Buy to Underperform. This notable shift points to worries over various obstacles that might hinder the automaker's performance in the future. Revised Price Target Indicates Ongoing Challenges The investment firm...

Continue Reading
Momcozy Celebrates Community Spirit with Charity Contest Success

Updated Category News Views 206

Momcozy Celebrates the Winners of the Charity Contest Momcozy, a leading global mother and baby brand, is excited to share the results of its 'Love in Action' Charity Contest. This initiative was part of a larger campaign aimed at promoting comfort, health, and well-being for mothers everywhere. In total, $30,000 was awarded to three remarkable organizations that are...

Continue Reading
FDA Approves SELARSDI™: A New Era in Biologics

Updated Category News Views 647

Exciting News: SELARSDI™ Receives FDA Approval Teva Pharmaceuticals, in collaboration with Alvotech, has made significant strides in the field of biosimilars. Recently, the U.S. Food and Drug Administration (FDA) granted approval for SELARSDI™ (ustekinumab-aekn), marking it as interchangeable with the established biologic, Stelara® (ustekinumab). This...

Continue Reading